[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carbapenem-resistant-enterobacteriaceae-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carbapenem-resistant-enterobacteriaceae-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,73,95,117,139,163,191,238,274,300],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644853","genomic-and-phenotypic-diversity-of-carbapenemase-producing-escherichia-coli-strains-circulating-in-southern-france-100644853",false,"NCT07676513","Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France.","Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France. The \"CARBA-COLI\" Study","CARBACOLI","Inclusion Criteria:\n\n* Not applicable to this study of an existing collection of Carbapenemase-producing Enterobacteriaceae strains.\n\nExclusion Criteria:\n\n* Not applicable to this study of an existing collection of Carbapenemase-producing Enterobacteriaceae strains.","ALL",{"count":19,"type":20},163,"ESTIMATED","3 Years","OBSERVATIONAL","Carbapenemase-producing Enterobacteriaceae (CPE) are classified as emerging Highly Resistant Bacteria (eHRB) because they expose infected patients to the risk of treatment failure due to the strains' resistance to last-line β-lactams, carbapenems, and frequent co-resistance to other classes of antibiotics, leading to increased morbidity and mortality. Their high epidemiogenic potential has enabled their global spread. In France, the incidence of Carbapenemase-producing Enterobacteriaceae is rising sharply, both in colonization and in infections. Parallel to this increase, Escherichia coli has become the most common Carbapenemase-producing Enterobacteriaceae (35% of strains in 2024, National Research Committee data), surpassing Klebsiella pneumoniae (24%).\n\nThe investigators hypothesize that the increase in the prevalence of carbapenemase-producing Echerichia coli is associated with a diversification of clones, enzymes, and their variants, and may pose a threefold threat: i) the spread of genes encoding carbapenemases within pathogenic extraintestinal Echerichia coli (ExPEC) pathogroups responsible for urinary tract infections and bacteremias, with a high risk of resistance spreading in the community, ii) the silent spread of Echerichia coli strains producing OXA-48 variants with reduced carbapenem hydrolytic activity, OXA-244 and OXA-484, which are not detected or poorly detected by conventionally used screening media and iii) the emergence of New Dehli Metallo-beta-lactamase (NDM) variants with high hydrolytic activity, such as NDM-5, within Echerichia coli clones possessing Penicillin-Binding Proteins (PLPs) with low affinity for antibiotics, leading to very high-level resistance and a therapeutic dead end in infected patients.",[25,26,27,28],"Antibiotic Resistance","Enterobacteriaceae Infections","Carbapenem-Resistant Enterobacteriaceae Infection","Colonization",[30,27,28,26],"Escherichia coli","NOT_YET_RECRUITING","2026-06-24",{"date":34,"type":35},"2026-06-30","ACTUAL",{"date":37,"type":20},"2026-06-01",{"date":39,"type":20},"2028-06-01",{"name":41,"class":42},"Centre Hospitalier Universitaire de Nīmes","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100514663","fecal-microbiota-transplantation-for-decolonization-of-carbapenem-resistant-enterobacteriaceae-100514663","NCT05981430","Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae","Oral Fecal Microbiota Transplant Capsules for Decolonization of Carbapenem-resistant Enterobacteriaceae: a Double-blind Randomized Controlled Trial","FMT","Inclusion Criteria:\n\n* All adult patients aged 18 or above admitted to the medical ward of Queen Mary Hospital, the teaching hospital of the University of Hong Kong\n* Rectal swabs or stool specimens showing the presence of CRE\n* Positive CRE specimen within one week of commencement\n\nExclusion Criteria:\n\n* Pregnancy\n* Severe immunodeficiency (e.g. advanced human immunodeficiency virus infection (CD4 lymphocyte count ≤200\u002Fmm3), myelosuppressive chemotherapy)\n* Significant neutropenia (absolute neutrophil count ≤1.0 x 109\u002FL)\n* Recent antibiotic use within 30 days prior to consent\n* Contraindications for capsule ingestion (dysphagia or gastrointestinal dysmotility).","18 Years","90 Years",{"count":55,"type":20},80,"INTERVENTIONAL",[58],"NA","The emergence of multidrug-resistant organisms (MDROs) has become one of the major threats to the healthcare system in Hong Kong in recent years. The situation is particularly worrisome for carbapenem-resistant Enterobacteriaceae (CRE). Taking Queen Mary Hospital as an example, the number of CRE cases has surged from 24 in year 2014 to 625 in year 2021. The case burden in Hong Kong is therefore substantial when all 43 public hospitals and institutions in Hong Kong are considered. With the widespread use of broad-spectrum antibiotics and active case screening, the number of CRE cases is expected to further increase in an exponential manner.\n\nGiven that colonization with MDROs is due to gut dysbiosis from antibiotic use, a normal intestinal microbiota is apparently crucial in protecting hosts from colonization with MDROs including CRE. Fecal microbiota transplantation (FMT), which involves the infusion of stool from a healthy donor to the gastrointestinal (GI) tract of a recipient, has gained popularity in recent years to restore colonic microbial diversity in various diseases associated with gut dysbiosis, e.g. Clostridium difficile (CD) infection, ulcerative colitis and even metabolic diseases. The investigators aim to conduct a double-blind randomized controlled trial to evaluate the benefit of FMT via upper GI delivery (oral capsules) on CRE clearance.",[27,61],"Fecal Microbiota Transplantation",[50,63],"CRE","2026-05-08",{"date":66,"type":35},"2026-05-13",{"date":68,"type":20},"2026-11-01",{"date":70,"type":20},"2028-06-30",{"name":72,"class":42},"The University of Hong Kong",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":52,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":43},"100403618","risk-factors-for-colonization-or-infection-with-carbapenem-resistant-enterobacteriaceae-in-children-100403618","NCT04535661","Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children","A Retrospective Single Center Study of the Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in PICU Hospitalized Children","Inclusion Criteria:\n\n* All children hospitalized in PICU of Children's Hospital of Fudan University from January 2018 to December 2019.\n\nExclusion Criteria:\n\n* discharge within 48 hours\n* patients had a positive culture for CRE before admission\n* incomplete clinical and demographic data","29 Days",{"count":82,"type":20},536,"Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly identified in children in China. Pediatric intensive care unit (PICU) is the high-risk area. However, data on the epidemiology of CRE in hospitalized children in PICU are limited. The objectives of this study are to characterize the risk factors for colonization or infection with CRE and describe the microbiologic characteristics of pediatric CRE isolates. The investigators will perform a single retrospective study from January 2018 to December 2019 at PICU of Children's Hospital of Fudan University .",[27],"RECRUITING","2026-03-13",{"date":88,"type":35},"2026-03-16",{"date":90,"type":35},"2021-03-01",{"date":92,"type":20},"2026-12-31",{"name":94,"class":42},"Children's Hospital of Fudan University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100605288","microbiological-and-clinical-characteristics-of-severe-infections-caused-by-carbapenem-resistant-enterobacterales-100605288","NCT07160569","Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales","Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales: A Prospective Multicenter Study in Southern Italy (the MICE Study)","MICE","Inclusion Criteria:\n\n1. age ≥ 18 years;\n2. isolation of CRE from a clinically relevant sample considered to be the site of infection: pneumonia, UTI, IAI, spondylodiscitis and BSI.\n3. Patients who by clinical practice have received at least one dose of the following drugs from ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol.\n4. Signature of Informed Consent\n\nExclusion Criteria:\n\n1. Subjects under 18 years of age\n2. absence of CRE infections",{"count":104,"type":20},100,"Severe infections caused by carbapenem-resistant Enterobacterales (CRE) represent a challenge for the clinicians, considering the high mortality rate of these infections. Data regarding the prevalence of CRE, clonal analysis, resistant genes (resistome) and virulence genes (virulome) molecular analyses, and clinical outcomes of infected patients are scarce. Thus, creating a network to Standardize and implement microbiological sourveillance could be crucial to answer this challenge. Our group consisting of the, UOC of Infectious Diseases and UOC of Microbiology (Prof Sanguinetti), the Microbiology Unit of the University of Catania (Prof. Stefania Stefani), the local Infectious Disease Unit (Dr Carmelo Iacobello) the Microbiology Unit of the \"Magna Graecia'' University (Prof. Giovanni Matera) and the UOC of Infectious and Tropical Diseases UMG Catanzaro Prof Enrico Maria Trecarichi, has already started a project with promising ad interim results on this topic.",[27],"2025-08-29",{"date":109,"type":35},"2025-09-08",{"date":111,"type":20},"2025-09-01",{"date":113,"type":20},"2026-08-31",{"name":115,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",4,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":124,"targetDuration":126,"studyType":22,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":43},"100599584","different-methods-of-aerosolized-polymyxin-b-inhalation-for-treating-carbapenem-resistant-gram-negative-bacterial-pneumonia-100599584","NCT07086391","Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.","A Prospective Clinical Study on Different Methods of Aerosolized Polymyxin B Inhalation for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Pneumonia","Inclusion Criteria:\n\n* Pneumonia diagnosed per Chinese Thoracic Society criteria (radiographic + clinical evidence).\n* Sputum culture-confirmed carbapenem-resistant Gram-negative bacteria susceptible to polymyxin B.\n* ≥3 days of aerosolized polymyxin B therapy.\n* Mechanically ventilated with an artificial airway.\n\nExclusion Criteria:\n\n* Polymyxin B aerosol use planned for \\\u003C3 days.\n* Terminal status (life expectancy \\\u003C48h).\n* Severe liver\u002Fkidney dysfunction (ALT\u002FAST \\>5× ULN; eGFR \\\u003C30 mL\u002Fmin).\n* No informed consent.",{"count":125,"type":20},144,"28 Days","Study Design:\n\nA randomized, open-label, parallel-group clinical trial comparing the efficacy and safety of jet nebulization versus vibrating mesh nebulization of sulfate polymyxin B in mechanically ventilated patients with carbapenem-resistant Gram-negative bacterial pneumonia.\n\nParticipants:\n\n144 patients (72 per group) will be enrolled from December 2023 to December 2025.\n\nInterventions:\n\nGroup A: 25mg polymyxin B + 5ml sterile water via jet nebulizer (respirator-assisted).\n\nGroup B: 25mg polymyxin B + 5ml sterile water via vibrating mesh nebulizer (respirator-assisted).\n\nBoth groups receive additional intravenous polymyxin B (2.0mg\u002Fkg loading dose, followed by 1.25mg\u002Fkg every 12h) starting 12h after nebulization.\n\nTreatment duration: 14 days.\n\nKey Procedures:\n\nNebulization parameters: Fixed ventilator settings (SIMV+PSV mode, tidal volume 8ml\u002Fkg, PEEP 6cmH₂O).\n\nBronchoalveolar lavage (BAL) and blood sampling:\n\nBAL fluid (BALF) and blood collected pre-nebulization (baseline), 1h post-nebulization, and at steady-state (days 3-7).\n\nBALF analyzed for polymyxin B concentration, urea nitrogen, and inflammatory mediators (IL-6, TNF-α, etc.).\n\nPrimary Outcomes:\n\nClinical efficacy:\n\nTotal response rate (cure + improvement). 28-day survival rate. Time to fever resolution and bacterial clearance.\n\nDrug exposure:\n\nPolymyxin B concentration in alveolar epithelial lining fluid (ELF) and blood.\n\nSecondary Outcomes:\n\nInflammatory response: Changes in BALF and serum IL-6, TNF-α, CRP levels.\n\nSafety:\n\nNephrotoxicity (changes in serum creatinine\u002Furea nitrogen). Airway complications (bronchospasm incidence).\n\nAssessment Timeline:\n\nClinical monitoring: Daily evaluation of vital signs, sputum volume, and ventilator parameters.\n\nLab tests: Blood tests (hematology, renal function, inflammatory markers) at baseline, days 3\u002F7\u002F14.\n\nMicrobiological evaluation: Sputum cultures on days 3\u002F7\u002F14.\n\nStatistical Analysis:\n\nEfficacy and safety endpoints compared between groups using t-tests or chi-square tests.\n\nA p-value \\\u003C0.05 will be considered statistically significant.",[27,129],"Pneumonia - Bacterial","2025-07-18",{"date":132,"type":35},"2025-07-25",{"date":134,"type":35},"2023-02-01",{"date":136,"type":20},"2026-02-01",{"name":138,"class":42},"Fujian Medical University Union Hospital",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":147,"sex":17,"minAge":4,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":56,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":43},"100506214","interventions-to-decrease-cre-colonization-and-transmission-between-hospitals-households-communities-and-domesticated-animals-100506214","NCT05871476","Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals","Interventions to Decrease Carbapenem Resistant Enterobacteriaceae Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals","I-CRECT","Inclusion Criteria:\n\n* All patients under 2 years old at the selected hospital are highly appreciated to join the study.\n\nExclusion Criteria:\n\n* Patients not from the selected hospital and individuals outside the selected province",true,"24 Months",{"count":150,"type":20},800,[58],"Carbapenem resistant Enterobacteriaceae (CRE) colonization of patients discharged from hospitals is a source of transmission to the community. In a cluster randomized controlled trial the effect of a bundle of interventions will be assessed on CRE transmission from CRE+ index patient discharged from hospital to HouseHold (HH) members. The districts in two provinces will be randomized to intervention or control. An information, communication, education and hygiene intervention, developed in collaboration with local health authorities, will aim to improve hygiene and decrease antibiotic (AB) use. The effect will be evaluated on CRE transmission between HH members, livestock and environment through consecutive CRE screening using fecal and hospital effluent samples cultured on carbapenem selective media. Knowledge, Attitudes, Practice surveys with smartphones will assess health seeking, AB use and hygiene adherence, hence detecting the effect of interventions. If transmission of CRE +\u002F- Colistin Resistant Enterobacteriaceae (CoRE, common among livestocks) is detected the source will be investigated including livestock and food, targeted information will be given and evaluated. In hospitals the effect of cohort care will be assessed on CRE acquisition, hospital acquired infection, treatment outcome, costeffectiveness and contamination in sewage water. Mechanisms of resistance, relatedness of CRE isolates in different One Health departments, and rate of CRE transmission from humans to animals and vice versa, will be assessed through Whole Genome Sequencing (WGS).",[154,27],"Antibiotic Resistant Infection","2025-06-18",{"date":157,"type":35},"2025-06-24",{"date":159,"type":35},"2022-07-01",{"date":34,"type":20},{"name":162,"class":42},"Hanoi University of Public Health",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":56,"phases":173,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":190},"100520050","efficacy-and-safety-of-colistimethate-sodium-for-injection-in-the-treatment-of-carbapenem-resistant-enterobacteriaceae-infection-100520050","NCT06051513","Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection：a Prospective, Open-label, Randomized Controlled, Multicenter Clinical Trial","Inclusion Criteria:\n\n1. Patients who can provide written informed consent or their informed consent can be provided by legal guardian\n2. Patients who are hospitalized\n3. Adults ≥18 years and ≤85 years of age\n4. Patients suspected of or diagnosed with hospital-acquired pneumonia (HAP, in a patient hospitalised for more than 48 hours or developing within 7 days after discharge from a hospital) or bloodstream infection caused carbapenem-resistant enterobacteriaceae (CRE) based on the culture results of the sample collected 5 days before the randomization or rapid diagnostic detection.\n\n   Rapid testing of respiratory or blood specimens should be used to enable early identification of CRE infection pneumonia. Patients can be randomized based on the results of the rapid test while awaiting results of cultures from the local laboratory. However, if the sample does not grow CRE in the local microbiology laboratory culture, these patients will be withdrawn from the study drug treatment.\n\n   Patients with HAP should fulfil one of the following systemic signs: 1)Fever (temperature \\>38°C) or hypothermia (rectal\u002Fcore temperature \\\u003C35°C);2)White blood cell (WBC) count \\>10,000 cells\u002Fmm3, or WBC count \\\u003C4500 cells\u002Fmm3, or \\>15% band forms and fulfil at least two of the following respiratory signs or symptoms:1)a new onset of cough (or worsening of cough);2)production of purulent sputum or endotracheal secretions;3)auscultatory findings consistent with pneumonia\u002Fpulmonary consolidation (e.g., rales, rhonchi, bronchial breath sounds, dullness to percussion, egophony);4)dyspnoea, tachypnoea or hypoxaemia (O2 saturation \\\u003C90% or pO2 \\\u003C60 mmHg while breathing room air).\n\n   Patients with bloodstream infection should fulfil one of the following criterion:1)fever(≥38 ℃);2)chills;3)hypotension(systolic \\\u003C90 mmHg, requiring vasopressors to maintain mean arterial pressure ≥60 mmHg,decreased by 30mmHg from baseline) ,and isolation of CRE from at least two blood culture collected from two different sites.\n5. Respiratory or blood specimen obtained for culture within 5 days prior to randomization, and after the onset of signs and symptoms of HAP or bloodstream infection (ideally before receipt of any systemic antibiotics).\n6. Patients whose APACHE II score is between 10 and 30.\n\nExclusion Criteria:\n\n1. Patients who received polymyxin for more than 48 hours in the 72 hours prior to randomization.\n2. Patients who received antibiotics more than 24 hours in the 72 hours prior to randomization, and after treatment，conditions of patients improved.\n3. Patient with history of serious allergy, hypersensitivity (eg, anaphylaxis), or any serious reaction to Colistimethate Sodium for Injection or other ingredients of it.\n4. Evidence of active concurrent pneumonia requiring additional antimicrobials treatment caused by Streptococcus pneumoniae，Haemophilus influenzae，Methicillin-resistant staphylococcus aureus，Vancomycin-resistant enterococcus，Mycoplasma pneumonia，Legionella pneumophila, respiratory syncytial virus, influenza virus, parainfluenza virus, Middle East Respiratory Virus, Mycobacteria, Aspergillus, Mucormycosis, Candida,etc. If these organisms are identified but it is deemed by the Investigator that no treatment is warranted and their presence does not significantly change the prognosis of the patient, then the patient may be considered for this study.\n5. Patients who are diagnosed with primary lung cancer (including small cell lung cancer\u002Fnon-small cell lung cancer patients) or other malignancy transferred to the lungs or other known post obstructive pneumonia. Patients who is known or suspected of active tuberculosis, cystic fibrosis, lung abscess, pyothorax or obstructive pneumonia.\n6. Patients with hematological malignancy such as leukemia, lymphoma and multiple myeloma.\n7. Patients with lung\u002Fheart transplantation or stem cell transplantation.\n8. Patient was immunocompromised and at risk of infection by opportunistic pathogens including, but not limited to the following:1) HIV (AIDS or CD4 \\\u003C200). 2) chemoradiotherapy within 3 months prior to randomisation. 3) Immunosuppressive therapy including maintenance corticosteroids (0.5 mg\u002Fkg prednisone per day or other equivalent glucocorticoid). 4) Absolute neutrophil count \\\u003C500\u002Fmm3.\n9. Patients with chronic liver failure with portal hypertension, acute hepatic failure or acute decompensation of chronic hepatic failure.\n10. Patients who participated in other clinical trials within three months.\n11. Patient was pregnant or breastfeeding. If either urine or serum β-hCG test was positive, the patient was excluded.\n12. Patient who have been previously enrolled in this study.\n13. Patients who have condionts that may affect the trial.\n14. Other conditions exist researchers thought are not suitable.","85 Years",{"count":172,"type":20},404,[58],"Colistin can be used to treat the infection caused by carbapenem-resistant enterobacteriaceae(CRE). In China, patients diagnosed with Hospital-acquired-pneumonia (HAP)or bloodstream infection caused by CRE are recruited, and randomly assigned to two groups, and in one group the patients accept treatment with colistin, however in another group, the patients accept treatment without colistin. The efficacy and safety of the treatment between the two groups are compared.",[27],[177,178,179,180],"Colistimethate Sodium for Injection","Hospital-acquired pneumonia","Bloodstream infection","Carbapenem-resistant Enterobacteriaceae","2025-05-14",{"date":183,"type":35},"2025-05-18",{"date":185,"type":35},"2023-11-27",{"date":187,"type":20},"2025-12-31",{"name":189,"class":42},"Southeast University, China",15,{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":56,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":43},"100363607","safety-and-efficacy-of-fecal-microbiota-transplantation-100363607","NCT04014413","Safety and Efficacy of Fecal Microbiota Transplantation","Safety and Efficacy of Fecal Microbiota Transplantation: A Pilot Study","Inclusion Criteria:\n\nConfirmed diagnosis of any of the following diseases:\n\n* Crohn's disease\n* Ulcerative colitis\n* Celiac disease\n* Irritable bowel syndrome\n* Functional dyspepsia\n* Constipation\n* Antibiotic-associated diarrhea or any antibiotic- associated complications\u002Fsymptoms\n* Metabolic syndrome such as diabetes mellitus and obesity\n* Multidrug-resistant infection\n* Hepatic encephalopathy\n* Multiple sclerosis\n* Pseudo-obstruction\n* Carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection\n* Multiple organ dysfunction\n* Dysbiotic bowel syndrome\n* MRSA enteritis\n* Pseudomembranous enteritis\n* Alopecia, autism\n* Graft-versus-host disease\n* Idiopathic thrombocytopenic purpura (ITP)\n* Atopy or allergy\n* Liver disease such as Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH)\n* Alcohol dependence\n* Psoriatic arthropathy that has suboptimal control of disease despite standard treatment.\n\nExclusion Criteria:\n\n* Known contraindication to all FMT infusion method such as nasoduodenal tube insertion, oesophago-gastro-duodenoscopy (OGD), enteroscopy, colonoscopy and enema\n* Any conditions that may render the efficacy of FMT or at the discretion of the investigators\n* Current pregnancy",{"count":199,"type":20},450,[58],"The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease states. Fecal microbiota transplantation (FMT), defined as infusion of feces from healthy donors to affected subjects, is a method to restore a balanced gut microbiota and has attracted great interest in recent years due to its efficacy and ease of use. FMT is now recommended as the most effective therapy for CDI not responding to standard therapies.\n\nRecent studies have suggested that dysbiosis is associated with a variety of disorders, and that FMT could be a useful treatment. Randomized controlled trial has been conducted in a number of disorders and shown positive results, including alcoholic hepatitis, Crohn's disease (CD), ulcerative colitis (UC), pouchitis, irritable bowel syndrome (IBS), hepatic encephalopathy and metabolic syndrome. Case series\u002Freports and pilot studies has shown positive results in other disorders including Celiac disease, functional dyspepsia, constipation, metabolic syndrome such as diabetes mellitus, multidrug-resistant, hepatic encephalopathy, multiple sclerosis, pseudo-obstruction, carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection, radiation-induced toxicity, multiple organ dysfunction, dysbiotic bowel syndrome, MRSA enteritis, Pseudomembranous enteritis, idiopathic thrombocytopenic purpura (ITP), and atopy.\n\nDespite FMT appears to be relatively safe and efficacious in treating a wide range of disease, its safety and efficacy in a usual clinical setting is unknown. More data is required to confirm safety and efficacy of FMT. Therefore, the investigators aim to conduct a pilot study to investigate the efficacy and safety of FMT in a variety of dysbiosis-associated disorder.",[203,204,205,206,207,208,209,210,211,212,213,214,215,27,216,217,218,219,220,221,222,223,224,225,226,227,228],"Crohn Disease","Ulcerative Colitis","Celiac Disease","Irritable Bowel Syndrome","Functional Dysphonia","Constipation","Clostridium Difficile Infection","Diabetes Mellitus","Obesity","Multidrug -Resistant Infection","Hepatic Encephalopathy","Multiple Sclerosis","Pseudo-Obstruction","Vancomycin Resistant Enterococci Infection","Multiple Organ Dysfunction Syndrome","Dysbiotic Bowel Syndrome","MRSA Enteritis","Pseudomembranous Enterocolitis","Alopecia","Autism","Graft-versus-host Disease","Idiopathic Thrombocytopenic Purpura","Atopy or Allergy","Liver Disease","Alcohol Dependence","Psoriatic Arthropathy","2024-08-21",{"date":231,"type":35},"2024-08-22",{"date":233,"type":35},"2019-07-15",{"date":235,"type":20},"2030-10-31",{"name":237,"class":42},"Chinese University of Hong Kong",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":56,"phases":248,"briefSummary":250,"conditions":251,"keywords":256,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":116},"100514518","phase-4-early-impact-therapy-with-ceftazidime-avibactam-via-rapid-diagnostics-100514518","NCT05979545","EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics","EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics Versus Standard of Care Antibiotics and Diagnostics in Patients With Bloodstream Infection, Hospital-acquired Pneumonia or Ventilator-associated Pneumonia Due to Pseudomonas Aeruginosa or Carbapenemase Producing Enterobacterales (RAPID)","RAPID","Inclusion Criteria:\n\n1. patient developed clinical symptoms compatible with bloodstream infection, hospital-acquired or ventilator-associated pneumonia (hospital-acquired and ventilator-associated pneumonia should fulfil US CDC NHSN criteria) AND,\n2. an appropriate specimen has been received by the participating laboratory - that is, a blood culture bottle showing Gram negative bacilli or a respiratory sample collected for clinical purposes showing Gram negative bacilli on Gram stain;\n\nExclusion Criteria:\n\n1. Refractory shock or comorbid condition such that patient not expected to survive more than 48 hours; OR,\n2. where the bloodstream infection is thought to be related to a vascular catheter and the catheter is unable to be removed; OR,\n3. treatment is not with the intent to cure the infection; OR,\n4. patient is incarcerated in a correctional facility; OR,\n5. patients previously randomised in this trial within the last 60 days.",{"count":247,"type":20},1900,[249],"PHASE4","The goal of this clinical trial is to propose a seamless intervention linking rapid bacterial isolate identification and antibiotic resistance gene detection and targeted antibiotic prescription to minimise time between infection onset and appropriate treatment in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales infections. This is an investigator initiated trial.\n\nThe primary hypothesis is that these interventions will lead to improved clinical outcomes amongst patients with hospital-acquired bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to carbapenem non-susceptible Pseudomonas aeruginosa or Enterobacterales, compared to standard antibiotic susceptibility testing.\n\nPatients will be randomised to either a control or intervention arm. Patients randomised to the intervention arm will have relevant specimens analysed by rapid microbiological diagnostics and will have early availability of ceftazidime-avibactam if appropriate. Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics will be available to these patients as per usual institutional practice.",[252,253,254,27,255],"Blood Stream Infections","Ventilator Associated Pneumonia","Healthcare Associated Infection","Hospital-acquired Pneumonia",[257,258,259,260,261,262,263,63,264,265],"rapid diagnostics","ceftazidime-avibactam","carbapenemase producing Enterobacterales","hospital-acquired","MDR","AMR","ASP","BCID2","PN Plus","2024-03-03",{"date":268,"type":35},"2024-03-06",{"date":270,"type":35},"2023-12-12",{"date":92,"type":20},{"name":273,"class":42},"National University of Singapore",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":147,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":299},"100535955","dynamics-of-colonization-and-infection-by-multidrug-resistant-pathogens-in-immunocompromised-and-critically-ill-patients-100535955","NCT06258551","Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients","DYNAMITE","Inclusion Criteria:\n\n* Admission to an intensive care unit or stem cell transplant unit (for allogeneic stem cell transplantation) within previous 24 hours\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* Pregnancy\n* History of inflammatory bowel disease (Crohn's disease, ulcerative colitis)\n* Gastrointestinal derivation (colostomy, ileostomy, etc.)",{"count":282,"type":20},1000,"The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization period and evaluate if some populations of specific bacteria increase or decrease the risk of acquiring an infection or becoming colonized by pathogenic bacteria. Participants will have the following samples collected during enrollment: stool samples (maximum 2x\u002Fweek), blood draws (1x\u002Fweek), oral swab (1x\u002Fweek).",[285,154,286,27,287,216,288,289],"Antimicrobial Drug Resistance","Clostridium Difficile","Extended Spectrum Beta-Lactamase Producing Bacteria Infection","Carbapenem Resistant Bacterial Infection","Vancomycin-Resistant Enterococcal Infection","2024-02-06",{"date":292,"type":35},"2024-02-14",{"date":294,"type":35},"2020-12-08",{"date":296,"type":20},"2026-06",{"name":298,"class":42},"The Methodist Hospital Research Institute",2,{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":170,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100532264","precise-treatment-of-ceftazidime-avibactam-in-patients-with-cro-infections-under-the-guidance-of-tdm-and-ppk-model-100532264","NCT06210542","Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model","Inclusion Criteria:\n\n1. 18-85 years old.\n2. Hospitalized participants in ICU who did not receive Ceftazidime Avibactam treatment within 15 days before joining the study.\n3. Participants with severe infection (refer to the 2022 sepsis3.0 guidelines for the definition of severe infection).\n4. at least one carbapenem-resistant Gram-negative pathogen (including but not limited to carbapenem-resistant Enterobacteriaceae and \u002F or Pseudomonas aeruginosa) was confirmed by bacterial culture in the primary infection site samples.\n5. sufficient respiratory secretions, blood and peritoneal effusion can be obtained within 48 hours before the first administration for bacterial culture and drug sensitivity test.\n6. intravenous injection of Ceftazidime Avibactam for more than 72 hours.\n7. understand compliance with research procedures and methods, voluntarily participate in this study, and sign informed consent in writing.\n\nExclusion Criteria:\n\n1. Participants are less than 18.\n2. Death within 72 hours after the start of treatment.\n3. Known resistance to β-lactam antibacterial drugs including cephalosporins, cephalosporin compound preparations containing β-lactamase inhibitors, or Those with a history of allergies to ceftazidime avibactam sodium for injection and its excipients.\n4. No indication for treatment with ceftazidime avibactam.\n5. Pregnant and lactating women.",{"count":307,"type":20},50,"The goal of this study is to evaluate the efficacy and safety of ceftazidime-avibactam(CAZ-AVI) in the treatment of critically ill patients with carbapenem-resistant organisms(CRO) infections (including dialysis patients and extracorporeal membrane oxygenation(ECMO) patients).",[310,27],"ECMO","2024-01-14",{"date":313,"type":35},"2024-01-18",{"date":315,"type":20},"2024-01",{"date":317,"type":20},"2026-12",{"name":319,"class":42},"Sichuan Provincial People's Hospital"]